Completed NA INTERVENTIONAL 4-arm NCT00843349

Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)

Fibroblast Growth Factor-23 Reduction in Predialysis Chronic Kidney Disease

Sponsor: Myles Wolf

Interventions 900 mg Phosphate Diet Ad Libitum Diet LC Placebo Lanthanum Carbonate

Updated 7 times since 2017 Last updated: May 1, 2013 Started: Jul 31, 2009 Primary completion: Feb 29, 2012 Completion: Mar 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Kidney Disease, this trial is completed. The trial is conducted by Myles Wolf and has accumulated 7 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2023 — Jul 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA
Jan 2021 — Dec 2022 [monthly]

Completed NA

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Myles Wolf
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)

Data source: University of Miami

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States